Document is current
Any future updates will be listed below
-
Authors
Lu, Chuanlong
Wang, Heng
Qiao, Maolin
Chang, Runze
Chen, Jinshan
Li, Lizheng
Fan, Keyi
Yan, Sheng
Zhang, Ruijing
Dong, Honglin
-
Funding
Funding for this research was provided by:
the Regional Cooperation Program of Shanxi Province, China (No. 202204041101038)
The Leading Talent Team Building Program of Shanxi Province, China (No. 202204051002010)
Construction and demonstration of molecular diagnosis and treatment platform for vascular diseases in Shanxi Province (No. SCP-2023-17)
Translational Medicine Engineering Research Center for Vascular Diseases of Shanxi Province (No. 2022017)
The Shanxi Provincial Science and Technology Department Centralized Guided Local Projects (No. YDZJSX2021C026)
The National Natural Science Foundation of China (No. 81770695, 81870354)
- License Information
-
More Information
Article History
Received: 18 September 2024
Accepted: 4 August 2025
First Online: 7 August 2025
Declarations
:
: The authors declare no competing interests.
: The study was approved by the Ethics Committee of Shanxi Medical University Second Hospital (approval No. DW2023051), and were also in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health. All experimental protocols adhered to the ARRIVE guidelines. The human data used in this study were approved by the Ethics Committee of Shanxi Medical University Second Hospital ([2024] YX No.(016)).
